Skip to main content

Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance

Objective

Antibiotic resistance (AMR), a major threat to human health, is increasing in all bacteria through antibiotic-induced selection, cross-species transfer of genetic mobile elements harbouring resistance genes, global transport and environmental waste. With an almost empty antibiotic pipeline, monoclonal antibodies (mAbs) and vaccines are increasingly recognized as important tools against AMR. Yet, available resources cannot finance all potential interventions, and choices need to be made according to costs of mAbs and vaccines, impact on the burden of AMR and prevention of its economic consequences. The PrIMAVeRa consortium will develop a web-based platform that combines advanced mathematical models with a comprehensive epidemiological repository. Systematic reviews will generate data to inform the model structure and parametrisation and select the most appropriate models for determining the AMR burden by pathogen, infection and target population. Deterministic continuous time models (ordinary differential equations [ODE]) and stochastic discrete time individual-based models with multiple modules will cover all relevant aspects of AMR, while Bayesian approaches will be used for cost-effectiveness analysis. The models will be calibrated in 8 EU countries based on the data coming from health information systems. The PrIMAVeRa consortium comprises a prominent collection of European research groups with expertise in AMR, vaccines, mAbs, mathematical and economical modelling. The proposal builds on established research collaborations and existing research infrastructures from EU- and IMI-funded research projects, such as EPI-Net (COMBACTE-MAGNET) and CLIN-Net and LAB-Net (COMBACTE-NET). The major deliverable will be an open access web-based user interface that will allow the wider scientific community to freely access and apply the models. This platform will also help healthcare authorities to make data-driven decisions on which vaccines and mAbs should be prioritised.

Call for proposal

H2020-JTI-IMI2-2020-23-two-stage
See other projects for this call

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV
Address
Vossstrasse 2 Geb 4040
69115 Heidelberg
Germany
Activity type
Research Organisations
EU contribution
€ 1 088 600

Participants (18)

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Netherlands
EU contribution
€ 1 373 550
Address
Heidelberglaan 100
3584 CX Utrecht
Activity type
Higher or Secondary Education Establishments
UNIVERSITE DE GENEVE
Switzerland
EU contribution
€ 436 275
Address
Rue Du General Dufour 24
1211 Geneve
Activity type
Higher or Secondary Education Establishments
UNIVERSITA DEGLI STUDI DI VERONA
Italy
EU contribution
€ 280 275
Address
Via Dell Artigliere 8
37129 Verona
Activity type
Higher or Secondary Education Establishments
DANMARKS TEKNISKE UNIVERSITET
Denmark
EU contribution
€ 478 275
Address
Anker Engelundsvej 1, Building 101A
2800 Kongens Lyngby
Activity type
Higher or Secondary Education Establishments
INSTITUT PASTEUR
France
EU contribution
€ 396 275
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
SERVICIO ANDALUZ DE SALUD
Spain
EU contribution
€ 274 275
Address
Avenida De La Constitucion 18
41071 Sevilla
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
LIETUVOS SVEIKATOS MOKSLU UNIVERSITETO LIGONINE KAUNO KLINIKOS
Lithuania
EU contribution
€ 139 275
Address
Eiveniu 2
50009 Kaunas
Activity type
Research Organisations
Department of Health
United Kingdom
EU contribution
€ 546 275
Address
Quarry House, Quarry Hill
LS2 7UE Leeds
Activity type
Research Organisations
INSTITUTO DE SALUD CARLOS III
Spain
EU contribution
€ 607 275
Address
Monforte De Lemos 5
28029 Madrid
Activity type
Research Organisations
ARES GENETICS GMBH
Austria
EU contribution
€ 129 275
Address
Karl-farkas-gasse 18
1030 Wien
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITE GRENOBLE ALPES
France
EU contribution
€ 129 275
Address
621 Avenue Centrale
38058 Grenoble
Activity type
Higher or Secondary Education Establishments
THE FEDERAL STATE SCIENTIFIC INSTITUTION SAINT-PETERSBURG SCIENTIFIC RESEARCH PASTEUR INSTITUTE OF EPIDEMIOLOGY AND MICROBIOLOGY
Russia
EU contribution
€ 109 275
Address
Mira Street 14
197101 Saint Petersburg
Activity type
Research Organisations
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 321 275
Address
University Offices, Wellington Square
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments
LIFE SCIENCE NETWORK GGMBH
Germany
EU contribution
€ 114 275
Address
Karlsruher Strasse 18
69126 Heidelberg
Activity type
Other
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Germany
EU contribution
€ 76 275
Address
Geschwister-scholl-platz
72074 Tuebingen
Activity type
Higher or Secondary Education Establishments
GLAXOSMITHKLINE BIOLOGICALS SA
Belgium
EU contribution
€ 0
Address
Rue De L Institut 89
1330 Rixensart
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PFIZER LIMITED
United Kingdom
EU contribution
€ 0
Address
Ramsgate Road
CT13 9NJ Sandwich
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
JANSSEN VACCINES & PREVENTION BV
Netherlands
EU contribution
€ 0
Address
Archimedesweg 4
2333 CN Leiden
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)